Moderate to Severe RA Treatment | ENBREL® (etanercept) Safety Info

1 2 3

IN MODERATELY TO SEVERELY ACTIVE RA PATIENTS

You may be thinking "Wait"

but their joints may be saying

Despite meaningful improvements with methotrexate alone, structural damage may still be progressing in your moderately to severely active RA patients. Consider ENBREL "NOW"

"I definitely wanted a treatment that would help me to manage my symptoms, as well as help to limit any progressive joint damage." Results may vary.

Consider starting ENBREL "NOW" in psoriatic arthritis patients for sustained inhibition of structural damage, substantial skin clearing, and improvement in signs and symptoms..*^†

Learn about ENBREL efficacy in psoriatic arthritis "NOW"

^*Mease PJ, Kivitz AJ, Burch FX, et al. J Rheumatol. 2006;33:712-721.

^†Data on file, Amgen.

Phil Mickelson, Champion golfer and ENBREL PsA patient since 2010

See Phil's Story

When you consider ENBREL, think of safety experience demonstrated over 10 years

ENBREL has been evaluated in clinical studies over the past 18 years* and has more than 10 years of continuous safety data in RA clinical trials.

Discover more about the history of ENBREL "NOW"

*Initial clinical research in rheumatoid arthritis (RA) patients began in 1993. ENBREL was FDA-approved to treat moderate to severe rheumatoid arthritis in 1998.

^†First tumor necrosis factor inhibitor approved in the US for moderate to severe RA, moderately to severely active polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis.

^‡DMARD = disease-modifying antirheumatic drug

Important Safety Considerations

Prescribing Information Medication Guide

Excellent support for your practice and your patients

Whether you need resources for your office or financial help and nurse support for your patients, we have you covered.

Take advantage of ENBREL Support™

Important Safety Information Prescribing Information Medication Guide

Indications

Moderate to Severe Rheumatoid Arthritis Supportive Data

You are leaving Enbrel.com/RheumPro

Please know that Amgen and Pfizer do not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

Continue Cancel

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy Terms of Use
This site is intended for US Audiences only.
©2011 Amgen, Inc., Thousand Oaks, CA 91320 and Pfizer Inc

E-mail this page to a colleague

Please correct the fields marked in red

Your E-mail

Colleague's E-mail

Send

This content is for US health care professionals only. Amgen and Pfizer will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.

Your e-mail was sent successfully.

Send another e-mail
Return to enbrel.com/RheumPro

Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

Continue

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.

Disease activity vs. structural progression in RA